Recent briefings covering the 30-day period through 2026-07-11 recorded no material discrete corporate events, new regulatory disclosures, or new corporate announcements for AbbVie Inc. Successive briefs dated 2026-06-09 through 2026-07-11 each noted the absence of new filings beyond routine continuations of existing disclosures [Brief - 2026-07-11]. No new product approvals, litigation outcomes, or executive changes were identified across the reviewed briefing cycle [Brief - 2026-07-03] [Brief - 2026-06-25].
AbbVie's trailing twelve-month revenue through 31 March 2026 stood at $62.82 billion, representing year-over-year growth of 12.43%. Net income for the same period was $3.64 billion, with a net margin of 5.79% and a gross margin of 67.37%. Operating margin was recorded at 24.41%. Earnings per share on a year-over-year basis declined 45.83%, while the reported P/E ratio stood at 125.36. Cash on hand was $9.39 billion against total debt of $64.50 billion [SEC 10-Q - ABBV - 2026-03-31].
Institutional ownership data reflects material position changes across several notable filers in the most recent reporting period. Bridgewater added 114% to its ABBV position, and Millennium added 61%, both representing substantial increases in reported holdings. Conversely, AQR Capital reduced its position by 23%, and Citadel reduced its position by 11% [SEC 13F - Bridgewater - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Citadel - Q2 2026]. No insider transactions were identified in the provided data for this period.
The prevailing macroeconomic rate environment shows the 10-year US Treasury yield at 4.57% and the 2-year at 4.16%, producing a normal yield curve with a spread of approximately 41 basis points [FRED DGS10] [FRED DGS2]. AbbVie carries a substantial debt load of $64.50 billion against a rate environment in which longer-duration borrowing costs remain elevated relative to recent historical norms [SEC 10-Q - ABBV - 2026-03-31].
This report was generated in response to material institutional position changes identified across multiple prominent 13F filers, including divergent directional moves between large quantitative and macro-oriented asset managers during the most recently available reporting quarter [SEC 13F - Bridgewater - Q2 2026] [SEC 13F - Citadel - Q2 2026].